Sinotherapeutics Inc. A (688247) — Capital Reinvestment Ratio
Latest as of December 2025:
0.44x
Sinotherapeutics Inc. A (688247) has a Capital Reinvestment Ratio of 0.44x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥95.33 Million) in capital expenditures (CN¥41.56 Million). See 688247 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.44x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥95.33 Million
CNY
Capital Expenditures
CN¥41.56 Million
CNY
Data as of
Dec 2025
Most recent filing
Sinotherapeutics Inc. A Capital Reinvestment Ratio (2020–2025)
This chart tracks Sinotherapeutics Inc. A's Capital Reinvestment Ratio across 6 annual periods.
Annual Capital Reinvestment Ratio for Sinotherapeutics Inc. A (2020–2025)
Year-by-year Capital Reinvestment Ratio for Sinotherapeutics Inc. A from 2020 to 2025. For live market cap and broader valuation context, see market cap of Sinotherapeutics Inc. A.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.44x | CN¥95.33 Million | CN¥41.56 Million | ▼ -40.2% |
| 2024 | 0.73x | CN¥130.23 Million | CN¥94.93 Million | ▼ -75.8% |
| 2023 | 3.01x | CN¥12.96 Million | CN¥38.96 Million | ▲ +24.8% |
| 2022 | 2.41x | CN¥73.18 Million | CN¥176.34 Million | ▲ +2094.4% |
| 2021 | 0.11x | CN¥145.77 Million | CN¥16.01 Million | ▼ -39.8% |
| 2020 | 0.18x | CN¥210.04 Million | CN¥38.34 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow